

2 July 2018

Announcement
National Stock Exchange of Australia
PO Box 283
Newcastle NSW 2300

Market announcement – Chinese Patent Granted for the Biosensor Platform

iQX Ltd (NSX:IQX) iQX, in partnership with iQnovate Ltd (**NSX: IQN**), is pleased to announce on behalf of their jointly owned company Life Science Biosensor Diagnostics Pty Ltd (LSBD), that LSBD has been granted a key patent for its biosensor platform in the People’s Republic of China. This will enable LSBD to enjoy patent protection in China until the year 2033.

This represents a significant step forward in the commercialisation of the biosensor platform technology and its multiple diagnostic applications worldwide, the first of which will be the launch of the saliva glucose biosensor in China.

The biosensor technology is being developed into a diagnostic platform which will revolutionise how consumers and patients monitor their health. AS previously announced to the market, LSBD has also commenced a development program with pilot tests for tumour biomarkers, hormones and immunology diagnostic tests. The groundbreaking technology means the biosensor platform can support a wide range of point-of-care diagnostic tests.

The first of these tests is the saliva glucose biosensor test, which has now reached its penultimate development milestone and will shortly commence the regulatory approval process in both Europe and Asia.

For further information, please contact:

Investor Relations Team
Email: investor.relations@theiqgroup.com.au
Phone: +61 2 8239 5400

About iQX Ltd

Eradicating disease through capital investment

iQX Ltd is an investment company and fund manager specializing in the life science sector, supporting physicians, scientists and entrepreneurs who are building innovation based businesses.

iqxinvestments.com